knowledge -WSS

knowledge

author：focus 2025-09-29 19:06:01 - browse：8

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The Affordable Care Act has saved billions in health care costs

focus

WSS

Zyn nicotine pouches become unlikely player in latest culture war

JPM: CVS says Medicare Advantage patients are impacting profits

Federal weight loss drug coverage is 30 years out of date

Chronically ill young patients struggle to find fertility info

The biotech scorecard for Q1: 17 stock

Federal weight loss drug coverage is 30 years out of date

Wikipedia

knowledge

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Medicare drug price negotiation legal challenge met with skepticism

DIEP, the 'gold standard' of breast reconstruction, is under threat

Goldman Sachs launches $650M fund for life science investments

Heart attack and stroke risk calculators need revising

The FDA must approve intranasal treatments for anaphylaxis

Continuity nursing helped my family in our darkest PICU moments

The Affordable Care Act has saved billions in health care costs

Medicare proposal to cover medical devices draws a mixed reaction

Philips to halt sales of sleep apnea machines in U.S.

explore

The FDA must approve intranasal treatments for anaphylaxis

Merck, Johnson & Johnson CEOs will testify on high drug prices

Antibiotic resistance and the global rise in human conflict

New weight loss drugs work. But how can they best be used?

Goldman Sachs launches $650M fund for life science investments

Biogen walks away from Aduhelm, years after polarizing approval

explore

focus

leisure time

focus